Kornimate/medical-research-clean huggingface dataset:
vitacov: vitamin d polymorphisms and severity of covid-19 infection

Conditions: COVID-19

Summary: vitamin d deficiency has been linked to hypertension, autoimmune, infectious and cardiovascular diseases which are risk factors for covid-19. moreover, covid-19 patients have a very high prevalence of hypovitaminosis d (turin data). taken together, we aim to investigate whether genetic variants in vitamin d-related genes contribute to a poor covid-19 outcome, particularly in hypertension and cv patients, proposing thus a personalized therapeutics based on vitamin d supplementation in order to reduce the severity and deaths.

collected data from turin university indicate that hospitalized patients have a very high prevalence of hypovitaminosis d. reports from china and italy show that hypertension presents an increased risk of covid-19-related death. otherwise, observational studies suggest that 25(oh)d induces protection against respiratory pathogens while large-scale studies indicate that serum 25(oh)d-level is inversely correlated to hypertension prevalence. recent published data (2020) shows that 66% of portuguese adults present vitamin d deficiency. heartgenetics' genetic database with more than 8.500 portuguese genotypes shows that the prevalence of vitamin d polymorphisms in this population is 4-fold higher than the eu average, increasing the risk of hypovitaminosis d.

Eligibility criteria:
inclusion criteria: * adults of 18 years and above. * covid-19 patients admitted with mild to severe disease (admission to isolation room) or critical patients (admission to icu). * available to comply with study protocol and sign informed consent. exclusion criteria: * patients diagnosed with covid-19 not admitted to hospital. * patients unable to provide informed consent.

Keywords: covid-19 vitamin d vitamin d polymorphisms
shr-1316 in combination with chemotherapy in patients with esophageal squamous cell cancer

Conditions: Advanced Esophageal Squamous Cell Cancer

Summary: the purpose of this study is to evaluate the progression-free survival (pfs) of chemotherapy combined with shr-1316 in patients with advanced esophageal squamous cell cancer.


Eligibility criteria:
inclusion criteria: 1. histologically or cytologically confirmed unresectable local advanced/recurrent or metastasis esophageal squamous cell carcinoma; 2. no previous systemic anti-tumor treatment; 3. subjects must have at least one measurable tumor lesion per recist 1.1; 4. ecog: 0-1; 5. adequate organ and bone marrow function; exclusion criteria: 1. allergic to monoclonal antibodies, any shr-1316 components,irinotecan , fluorouracil ; 2. prior therapy as follow: 1. anti-pd-1 or anti-pd-l1; 2. any experimental drugs within 4 weeks of the first dose of study medication; 3. received major operations or serious injuries within 4 weeks of the first dose of study medication; 4. received last dose of anticancer therapy (including chemotherapy, radiotherapy, targeted therapy, etc.) within 4 weeks of the first dose of study medication; 3. not recovered to ≤ctcae 1 from adverse events (except for hair loss) due to a previously anti-tumor treatment; 4. subjects with any active autoimmune disease or history of autoimmune disease; 5. pregnancy or breast feeding;
kinematics of lower limb, pain and function of the women with patellofemoral pain syndrome

Conditions: Patellofemoral Pain Syndrome

Summary: assess pain, function, trunk and lower limbs kinematic during functional tasks after hip muscle strengthening versus hip muscle strengthening and sensory motor training in lower limbs.


Eligibility criteria:
inclusion criteria: * sedentary women, * previous knee pain last 3 months in at least two of the following activities: sitting for long periods, walk up or down stairs, squat, running and jumping exclusion criteria: * lower limb surgery, * patella displacement * knee instability * heart or locomotor disorders which might influence the evaluation
screening for abdominal aortic aneurysm and popliteal artery aneurysm

Conditions: Aortic Aneurysm, Abdominal; Popliteal Artery Aneurysm

Summary: observational, prospective, cohort study to evaluate, by an opportunistic screening program based on vascular ultrasound, the prevalence and characteristics of abdominal aortic aneurysm (aaa) and popliteal artery aneurysm (paa) in a female population as well as the prevalence and characteristics of paa in male population.

abdominal aortic aneurysm (aaa) remains a highly topical issue given the potentially dramatic consequences associated with its rupture. in men, the prevalence of aaa is declining, probably due to improved management of risk factors. however, the most recent studies and international recommendations have reaffirmed that screening for aaa in men is still important and cost-effective. in contrast, data regarding the risk and characteristics of aaa in women are very limited and outdated. for this reason, the recommendations are contrasting and not univocal. about 35% of patients with aaa have a second aneurysm more distally. popliteal artery aneurysm (paa) is the most common. like aaa, paa is often asymptomatic and its main complication is thrombotic occlusion resulting in acute/chronic ischemia of the affected limb and a high prevalence of permanent sequelae (mainly amputation). data on epidemiology and risk factors of paa are very limited in men and absent in women. in addition, the benefit of paa screening has never been assessed so far. the aim of this study is to evaluate, by an opportunistic screening program based on vascular ultrasound, the prevalence and characteristics of aaa and paa in a female population as well as the prevalence and characteristics of paa in male population. the project represents the first screening program for popliteal aneurysm. finally, the results will allow us to better assess need for and modalities of a screening program.

Eligibility criteria:
inclusion criteria: * women aged ≥65 years who are current smokers * men aged ≥65 years * women or men aged ≥55 years with family history (first-degree relatives) for abdominal aortic aneurysm (aaa) or popliteal artery aneurysm (paa) exclusion criteria: * patient with known diagnosis of aaa or paa * patient already operated for aaa or paa * aaa/paa screening or arterial assessment of lower limbs within the last 12 months * inability to understand and/or sign study consent * inability to access follow-up controls

Keywords: abdominal aortic aneurysm popliteal aneurysm screening
effects neuromuscular taping technique on upper limbs edema in cardiac surgery patients

Conditions: Edema Limbs

Summary: this study aims to verify the efficacy of the decompression technique of neuromuscular taping on cardiac surgery patients in whom edema of the upper limbs occurs due to post-operative water overload.


Eligibility criteria:
inclusion criteria: * cardiac surgery patients with postoperative edema of the upper limbs due to water overload exclusion criteria: * absence of edema, * previous mastectomy and lymphadenectomy, * surgery or fractures or infection of the upper limb, * previous or current deep vein thrombosis.
acute and long term effects of vns on memory in patients with refractory epilepsy

Conditions: Refractory Epilepsy

Summary: refractory epilepsy patients implanted with a vagus nerve stimulator perform a memory test at baseline in three conditions: invasive vagus nerve stimulation (vns), transcutaneous vagus nerve stimulation (tavns) and sham stimulation. after 6 weeks of vns treatment, the memory test is repeated in two condition: invasive vagus nerve stimulation (vns) and sham stimulation. the endpoint of this experiment is assessing the effect of vns and tavns on memory performance.

previous studies underlined the potential of both invasive as transcutaneous auricular vagus nerve stimulation to ameliorate certain cognitive functions. in this randomized, controlled cross-over within-subjects study, a memory test is conducted in patients with refractory epilepsy who are implanted with a vagus nerve stimulation. the memory test consists out of a word recognition paradigm based on the study of clarck et al. published in 1999 in nature neuroscience. testing is performed at baseline (before start of the stimulation) and after 6 weeks of treatment with vagus nerve stimulation. during the first session, the patients complete the word recognition task during three interventions: * invasive vagus nerve stimulation * transcutaneous vagus nerve stimulation (cymba concha) * sham vagus nerve stimulation (no stimulation) during the second session, the patients complete the word recognition task during two interventions: * invasive vagus nerve stimulation * sham vagus nerve stimulation (no stimulation) the goal is to investigate if invasive vagus nerve stimulation and transcutaneous nerve stimulation can influence (i.e. improve) the performance on the memory task and if this performance is improved after 6 weeks of vns treatment.

Eligibility criteria:
inclusion criteria: * refractory epilepsy * treated with vagus nerve stimulation * iq \>= 70 and able to perform the memory task exclusion criteria: * iq \< 70

Keywords: vagus nerve stimulation transcutaneous vagus nerve stimulation word recognition paradigm
effect of diaphragmatic training on urgency urinary incontinence in postmenopausal women

Conditions: Urge Incontinence; Urinary Incontinence; Postmenopausal Disorder

Summary: the purpose of this study was to determine the effect of diaphragmatic training on urgency urinary incontinence in postmenopausal women.

urgency urinary incontinence affects 9-13% of women, increasing with age and impacting daily activities, quality of life, depression, and social isolation. it is a significant source of dependency among the elderly and a factor in nursing home admissions. untreated incontinence can lead to falls, infections, and loss of independence. conservative management is the first-line therapy, but pelvic floor muscle training is a potential treatment method. this study aims to evaluate the effectiveness of diaphragmatic training on urinary incontinence in postmenopausal women.

Eligibility criteria:
inclusion criteria: * postmenopausal women suffer from uui. * they will be multipara more than 1. * their age will range from 55-65 years old. * their body mass index (bmi) will range from 25-29.9 kg/m2.. * they will experience menopause at least for 3 years. exclusion criteria: * urinary tract infection * previous surgery for urinary incontinence * upper motor neuron diseases * history of genito-urinary cancer * previous pelvic irradiation * pure stress urinary incontinence * genital prolapse * diabetes mellitus * pace maker
research of the eml4-alk gene expression in the pleural effusion or tumor tissue from lung cancer patients

Conditions: Lung Cancer Patients

Summary: we wants to analyse the eml4-alk mutation rate in the patients who have non-small cell lung cancer.


Eligibility criteria:
inclusion criteria: * 20 or more than 20 years of age * the pathological diagnosis confirmed lung cancer * patients have achieved pleural effusion, or surgical biopsy to obtain tumor tissue specimens * the patient had signed inform consent exclusion criteria: * pleural effusion or tumor tissue can not be obtained * the patient is not suitable to join the research according to the judgement by the investigator

Keywords: lung cancer
fdg pet-scan analysis of evolutivity of non-surgical aneurysm of abdominal aorta

Conditions: Medically-treated Aneurysm of Abdominal Aorta

Summary: the primary aim of the study is to determine if the evolutivity of global and segmentary captation of fdg-f18, which can be measured in the wall of abdominal aorta aneurysm, is predictive of the 9 month evolution of diameter and volume of the aneurysm, measured globally and segmentary in angioscan.


Eligibility criteria:
inclusion criteria: * aaa with a minimum diameter of 40 mm, calculated with a standardized method * no indication for an immediate surgery or endoprothesis implantation * age above 18 (except for patient under supervision) * patient having read the information letter and signed the informed consent exclusion criteria: - aaa should have no other specific cause than atherosclerosis

Keywords: aneurysm of abdominal aorta 18f-fluorodesoxyglucose (fdg-f18)
vitamin d level vs semen parameters

Conditions: Male Infertility

Summary: * infertility is defined as the inability of a sexually active couple to conceive after 1 year of regular intercourse without contraception, affects approximately 15% of couples, and male factors are the cause in 20% -50% of cases. * infertility of unknown origin is classified into idiopathic male infertility and unexplained male infertility according to semen quality.

-idiopathic male infertility is known as idiopathic oligoasthenoteratozoospermia, which indicates that the men have an unexplained reduction of semen quality. in contrast, unexplained male infertility is defined as infertility of unknown origin with normal sperm parameters. furthermore, optimal strategies for treating idiopathic male infertility have also remained unclear. * data from studies in humans suggest that vitamin d receptors are present in testis, epididymis, prostate and seminal vesicles. the level of expression varies, being higher in epididymis and seminal vesicles. * vitamin d receptors expression was also evident in leydig cells, as well as in normal and abnormal sperm, with the acrosomal region and the neck being the sites with the most abundant messenger ribonucleic acid expression. * the 1,25(oh)2 d3 molecule increases intracellular calcium concentrations, sperm motility and acrosin activity, and reduces triglyceride content in sperm, actions that significantly contribute to fertilising capacity within the female reproductive tract.

Eligibility criteria:
inclusion criteria: * infertile male patients without any detectable cause with normal clinical examination and abnormal semen parameters. exclusion criteria: * cases with known etiology or apparent physical finding ,leukocytospermia, diminished testicular volume ,varicocele or an abnormal hormonal profile. * couples with combined male and female factor will be excluded.
high calorie high protein nutrition supplementation in advanced heart failure

Conditions: Heart Failure

Summary: in this study, the investigators will determine the impact of a high calorie and high protein nutrition supplementation strategy on quality of life in participants with advanced heart failure. the investigators hypothesize that participants with advanced heart failure who receive the high calorie high protein nutrition supplementation strategy will experience an improvement in quality of life compared to those patients that receive usual care.

this is a single center, prospective randomized open with blinded endpoint (probe) trial with an individual follow-up time of 30 days duration designed to determine the impact of a high calorie high protein nutritional supplementation strategy on quality of life and functional outcomes in adults with malnutrition advanced systolic heart failure. 48 participants will be randomized in a stratified fashion by gender and subjective global assessment (sga) class (b versus c). study subjects will receive a calorie and protein nutritional supplement, ensure original, manufactured by abbott laboratories for 30 days after hospital discharge. the study site will be columbia university irving medical center. investigators will be blinded to group assignment and dietary recalls until the completion of the study.

Eligibility criteria:
inclusion criteria: * patients aged ≥ 18 years * hospitalized at columbia university irving medical center/new york presbyterian hospital * left ventricular ejection fraction \<=40% * at least mild malnutrition as determined by the subjective global assessment (sga) exclusion criteria: * inability to eat orally * inability to eat independently * history of dysphagia * allergy to nutritional supplement * need for inotrope and/or mechanical support at hospital discharge * listed for heart transplant * insulin dependent diabetes and/or most recent a1c \>7% * having two or more results of a serum potassium \>5.0 mmol/l during hospitalization or history of serum potassium \>6.0 mmol/l, and/or at an excessive risk of hyperkalemia as judged by the investigators * severe renal insufficiency (estimated glomerular filtration rate \<30 ml/min/1.73m\^2 at discharge) * cirrhosis * history of bariatric surgery * nursing home residence * history of persistent noncompliance with treatment recommendations as judged by the investigators
a comparison of surgical preparations and wound infection rates for elective cesarean sections

Conditions: Wound Infection

Summary: the purpose of this study is to find out if chlorhexidine gluconate solution is better at reducing the rate of wound infection after cesarean section compared to povidone-iodine.

wound infection is a universal potential morbidity to any type of surgery. over the years many studies have been completed to evaluate ways to decrease this morbidity. recent literature has looked at different types of surgical solutions used in pre-operative cleansing. chlorhexidine and povidone-iodine are two standard surgical prep solutions used on a global scale. the most recent literature has shown that chlorhexidine has a decreased wound infection rate for longer surgeries. cesarean section, as a surgical time, varies from 20 - 60 minutes. there has been no known literature regarding wound infection rates using these two solutions in elective cesarean sections. this trial will review the rates of wound infection using chlorhexidine and povidone-iodine during elective cesarean section and determine if there is any statistically significant difference between the two solutions. the results could potentially decrease wound infection rates, decrease morbidity, decrease hospital length of stay, and help to guide further surgical management.

Eligibility criteria:
inclusion criteria: * age \>19 years * gestational age \> 37 weeks * booked elective cesarean section exclusion criteria: * gestational age \< 37 weeks * premature rupture of membranes * onset of labor prior to procedure * evidence of maternal sepsis; maternal fever \> 38.5c * lscs for emergency issues: non-reassuring fetal status, placental abruption, failed induction

Keywords: infection sepsis povidone-iodine chlorhexidine gluconate fever erythema leukocytosis drainage vaginal discharge elective cesarean section
study of circulating microparticles in giant cell arteritis

Conditions: Giant Cell Arteritis; Acute Phase

Summary: to demonstrate that microparticles (mps), having a powerful procoagulant potential, are in larger amounts in the blood of patients with histologically proven giant cell arteritis (gca), compared with patients matched for age, sex and with or without inflammatory syndrome.


Eligibility criteria:
for gca group: inclusion criteria: * men and women ≥ 18 years of age patient affiliated to social security regimen * informed and having signed the consent form to take part in the study. * diagnosis of gca, meeting at least 3 of the following 5 american college of rheumatology (acr) criteria for the diagnosis of gca, including inflammatory syndrome and having * either temporal artery biopsy showing characteristic gca abnormality * or inflammatory arteritis on imaging examination exclusion criteria: * persons under protection of the court or guardianship * inability to understand or to follow study procedures * dementia * cancer diagnosed within the previous 5 years (except for non-melanoma skin cancer or in situ carcinoma of the cervix)non-contributory or inconclusive temporal artery biopsy * any conditions that might interfere with mps level: diabetes, recent endo-arterial gesture, current treatment with corticosteroids. * participation in another ongoing clinical trial current anticoagulant therapy * active infectious disease
at-risk and vulnerable individuals to infection with covid-19 and proactive intervention with integrated health and social care

Conditions: Emotional Distress; Quality of Life; Mental Health

Summary: this randomized control trial aims to explore a data-driven, proactive approach to identifying patients at greatest risk during the pandemic, and assess the impact of an embedded system navigator in a primary health care setting. the system navigator works one-on-one with patients to identify and provide support to their biological, psychological and social needs (e.g. income, housing, food security). investigators are doing this study to find out whether proactive identification of vulnerable patients and linking to a system navigator leads to reduction in emotional distress associated with managing complex health conditions and unmet social needs during covid-19, compared to usual care. investigators will involve approximately 180 patients from primary care clinics that are a part of the university of toronto practice-based research network (utopian). the information from this study will be used to help us understand how proactive engagement within a primary health setting can help to improve the health of patients during covid-19, and beyond.


Eligibility criteria:
inclusion criteria: * at-risk and vulnerable patients of primary care organizations who are 60+ and have one or more of: 1. chronic condition (diabetes, chf, cad, copd or asthma) 2. serious mental illness (schizophrenia or bipolar disorder) 3. anticipated to live in poverty and/or be homeless/underhoused exclusion criteria: * patients unable to provide informed consent

Keywords: social determinants of health covid-19 primary health care proactive care
longitudinal study of gene expression in the human placenta during first-trimester and full-term pregnancy at the single cell level

Conditions: Pregnancy Related

Summary: the single nucleus rna-seq approach allows the placental transcriptome to be analyzed from nuclei, thus preserving the integrity of placental syncytium. this approach is feasible on small fragments of villi and offers for the first time the possibility to consider the characterization of gene expression within the structural unit of the human placenta during pregnancy (at the 1st trimester and childbirth)

chorionic villus biopsies are routinely performed between 11sa and 15sa at the fetal medicine unit́ of the port-royal maternity hospital (cpdpn cochin) after the patient has signed an information and consent form for the genetic analysis. the patient will be asked to participate to the villirnaseq project and will sign the consent form of the study. after the cytogeneticist observation, a villi fragment will be snap-frozen in liquid nitrogen and stored at -80°c until use. each patient sampled in the first trimester is followed until the end of the pregnancy. at delivery, cesarean section or vaginal delivery, a placental sample will be snap-frozen in liquid nitrogen and stored at -80°c until use. isolation, sorting and encapsidation of nuclei, rna libraries preparation and sequencing will be carried out using 10x genomics technology. state-of-the-art computational analyses to decipher trajectories and cell-to-cell communications.

Eligibility criteria:
inclusion criteria: * age 18 to 50 * progressive monofoetal pregnancy between 11 and 15 weeks of amenorrhea * patient with prenatal medical indication and requesting chorionic villus biopsy with cytogenetic analysis or molecular genetics * patient scheduled for delivery at port-royal maternity hospital exclusion criteria: * minor patient * multiple pregnancy * patient's objection * without health insurance * patient under guardianship or curatorship

Keywords: placenta single nuclei rna-seq preeclampsia pregnancy outcomes